New BioCrossroads' Board Members Reflect the Extraordinary Strengths Across Indiana's Life Sciences Ecosystem

INDIANAPOLIS (June 20, 2026) – BioCrossroads, the CEOs of Indiana Corporate Partnership initiative established  to advance, grow, and invest in Indiana’s life sciences sector, today announced four new appointments to its Board of Directors: Kirk Bailey, Vice President, Research & Engineering at Zimmer Biomet; Patrick McGill, MD, DHA, MBA, Network President & CEO of Community Health Network; Sarah O’Keefe, PhD, Group Vice President, Product Research & Development at Eli Lilly and Company; and Milan Radovich, PhD, Senior Vice President and Chief Scientific Officer at Caris Life Sciences.

The new members bring leadership across medical devices, healthcare delivery, pharmaceutical research and development, precision medicine, and data-driven science, reflecting the breadth of expertise that personifies Indiana’s life sciences ecosystem.

Kirk Bailey, Vice President, Research & Engineering at Zimmer Biomet, brings extensive experience in medical technology, engineering leadership, and musculoskeletal innovation. As a senior leader at one of the world’s leading orthopedic companies, Bailey has helped advance the technologies, systems, and product development capabilities that support Zimmer Biomet’s mission to alleviate pain and improve quality of life for people around the world. His perspective will be valuable as BioCrossroads continues to support Indiana’s global leadership in medtech and musculoskeletal health..

Patrick McGill, MD, DHA, MBA, Network President & CEO of Community Health Network, brings more than 20 years of clinical and healthcare leadership experience to the Board. A board-certified family medicine physician, Dr. McGill has held senior leadership roles focused on transformation, analytics, clinical strategy, value-based care, and technology-enabled healthcare delivery. His experience leading one of Indiana’s major health systems will help inform BioCrossroads’ work at the intersection of life sciences, healthcare innovation, clinical research, and healthcare delivery.

Sarah O’Keeffe, PhD, Group Vice President, Product Research & Development at Eli Lilly and Company, brings deep scientific and pharmaceutical development expertise. In her role at Lilly, Dr. O’Keeffe helps lead the teams responsible for translating promising discoveries into scalable medicines, including formulation, drug delivery, manufacturing process development, clinical supply, and packaging. Her experience at the intersection of research, development, and advanced manufacturing aligns closely with Indiana’s position as a global leader in biopharmaceutical innovation and production.

Milan Radovich, PhD, Senior Vice President and Chief Scientific Officer at Caris Life Sciences, brings expertise in precision medicine, oncology, genomic medicine, translational research, clinical trials, target discovery, and drug development. In his role at Caris, Dr. Radovich leads data-driven scientific advancements and works closely with academic and biopharma collaborators to advance research in precision medicine. His leadership adds important perspective as BioCrossroads continues to support emerging areas of life sciences innovation, including data-enabled discovery and personalized healthcare.

“These new Board members reflect the extraordinary depth and breadth of leadership that make BioHeartland Indiana’s  ecosystem so strong,” said Vince Wong, President and CEO of BioCrossroads. “Kirk, Patrick, Sarah, and Milan bring world-class expertise across medtech, healthcare, pharmaceutical development, and precision medicine. Their perspectives will help guide our work as we continue to connect partners, accelerate innovation, strengthen talent pipelines, and advance Indiana’s leadership in life sciences.”

###

About BioCrossroads
Established as a catalyst to advance, grow, and invest in Indiana’s life sciences sector, BioCrossroads is an initiative of the CEOs of Indiana Corporate Partnership (CICP). BioCrossroads advances Indiana’s life sciences industry by connecting corporate, academic, and philanthropic partners; facilitating investments in promising startups and building new enterprises; and educating through conferences, reports, and market development knowledge. The initiative fosters public-private collaboration across Indiana’s life sciences sector and helps strengthen the companies, talent, innovation, manufacturing, and partnerships that define the state’s ecosystem. To learn more about BioCrossroads, visit biocrossroads.com.

Indiana's Life Sciences Ecosystem in 2025

Advancing BioCrossroads' 10-Year Strategy

INDIANAPOLIS (March 18, 2026)—BioCrossroads today released its 2025 Annual Report, highlighting another landmark year for Indiana’s life sciences ecosystem. The report highlights BioCrossroads’ efforts to support robust talent pipelines, unprecedented economic impact, and national recognition of Indiana’s leadership in life sciences.

Indiana remained number one in the nation for life sciences and pharmaceutical exports. The report also highlights continued growth and momentum across the state’s life sciences and healthcare sectors: $102 billion total economic activity across Indiana’s life sciences industry; 70,000 Hoosiers employed in life sciences across 3,312 establishments; $177,000 average annual wage in life sciences; 386,100 healthcare workers across Indiana; 36 venture capital deals totaling approximately $190 million invested in Indiana life sciences companies in 2025.

“By crossing the $100 billion threshold of total economic contribution, Indiana’s life sciences sector has reached a remarkable milestone that reflects decades of collaboration among industry, academia, philanthropy, government, and investors,” said Vince Wong, President and CEO of BioCrossroads. “More importantly, it shows that Indiana’s model of connecting research, development, manufacturing, talent, and entrepreneurship is producing real results.”

The Annual Report outlines progress across BioCrossroads’ 10-year Strategic Roadmap for Advancing Indiana’s Life Sciences Industries launched in January 2024, detailing major progress in advancing innovation, manufacturing, workforce development, capital formation, and ecosystem collaboration that are strengthening Indiana’s position as a global life sciences leader.

Last year, BioCrossroads expanded support for startups and founders through the Startup Catalyst Center, including the launch of the AXIS Mentoring Program, which connected 14 founders with 36 mentors and delivered more than 50 hours of mentoring in its first year. The organization also helped support the launch of Indiana University Launch Accelerator for Biosciences (IU LAB) to accelerate the commercialization of university-based life sciences research.

Indiana strengthened its role as a global manufacturing hub, highlighted by securing its designation as the Radiopharmaceutical Capital of the World™, reflecting the state’s leadership in research, development, manufacturing, logistics, and specialized workforce capabilities for the rapidly growing radiopharmaceutical sector.

BioCrossroads continued to build talent pipelines through efforts such as the BioTrain initiative, part of the federally funded Heartland BioWorks Tech Hub powered by the Applied Research Institute (ARI) and supported by the federal Economic Development Administration (EDA). The program is developing new biomanufacturing training capacity in partnership with Ivy Tech Community College and Purdue University, leveraging the Midwest-region exclusive curriculum partnership with the National Institute of Bioprocessing Research and Training (NIBRT). BioCrossroads also was designated to serve as the Industry Talent Associations for Healthcare and Life Sciences sectors to help launch the Indiana Career Apprenticeship Pathway (INCAP) to build scalable pathways into high-demand healthcare and life sciences careers, starting with high-school work-based apprenticeships. In 2025, BioCrossroads also expanded statewide and national engagement through convenings, partnerships, and communications efforts designed to elevate Indiana’s life sciences thought leadership.

The 2025 BioCrossroads Life Sciences Summit, held in partnership with AgriNovus Indiana, brought together more than 350 leaders to explore Indiana’s emerging leadership in One Health, connecting human, animal, and plant health innovation. BioCrossroads hosted four FrameWORX events, bringing together more than 500 industry participants to discuss key issues including research commercialization, workforce development, and emerging technologies.

###

About BioCrossroads
An initiative of the CEOs of Indiana Corporate Partnership (CICP), BioCrossroads is a catalyst for Indiana’s life sciences sector, advancing the state’s position as a global leader in research, development, manufacturing, and healthcare innovation. Through strategic initiatives, industry partnerships, and ecosystem development, BioCrossroads supports the growth of life sciences companies, talent, and investment across Indiana.  It supports the region’s existing enterprises and encourages new business development. The initiative fosters public-private collaboration by uniting a diverse range of academic, industry, and philanthropic stakeholders, all collectively focused on advancing Indiana’s life sciences sector. Committed to supporting the growth of capital investments and talent development, BioCrossroads provides support to both existing and new life sciences enterprises, including the Indiana Health Information Exchange, OrthoWorx, and the Indiana Biosciences Research Institute. BioCrossroads champions the advancement of cutting-edge research and development, plays a crucial role in building and nurturing a robust talent pipeline, and is dedicated to establishing Indiana as a thriving hub for life sciences manufacturing. To learn more about BioCrossroads, visit biocrossroads.com.

CICP Launches Catalyst Scholars Fund to Drive Advanced Chemistry Innovation in Indiana

Indianapolis (March 5, 2026) – The Central Indiana Corporate Partnership (CICP) has announced the launch of the Catalyst Scholars Fund, which marks the first phase of a broader Advanced Chemistry strategy for Indiana. The strategy involves a coordinated effort to position Indiana as the national leader in the development and deployment of technologies needed to reshore and secure critical supply chains for medicines, animal health products, and agricultural inputs, which is a national security priority.

The Catalyst Scholars Fund is a five-year initiative to enable Indiana’s leading STEM higher education institutions, including its four R1 research institutions (Indiana University, Purdue University and the University of Notre Dame) along with Rose-Hulman Institute of Technology to attract world-class research teams in Advanced Chemistry through strategic cluster and eminent scholar recruitment. The Fund will provide matching support for major equipment, laboratory infrastructure, and startup packages, strengthening the State’s ability to attract and retain top research talent with the expertise and capabilities to develop new technologies with translational potential that can be deployed to strengthen domestic supply chains. 

Supported by a $69.4 million grant from Lilly Endowment Inc. to the CICP Foundation Inc. and matching commitments from participating universities, the Catalyst Scholars Fund, spearheaded by CICP and powered by its branded initiatives, BioCrossroads and AgriNovus Indiana, will enable these Indiana higher education institutions to recruit 25 to 45 world class faculty and their teams over five years to tackle industry informed grand challenges in analytical chemistry, novel macromolecular chemistries, automation, and artificial intelligence applications in bioscience manufacturing. 

Leveraging Indiana’s unique strengths, including global life sciences leaders Eli Lilly and Company, Elanco Animal Health, and Corteva and these world-class research and teaching institutions and the State’s position as the nation’s leading exporter of life science products, the initiative will accelerate new research and translation of platform technologies. Together, these tools and capabilities are relevant across human health, animal health, and plant science, serving as a compelling example of the power of Indiana’s One Health ecosystem. 

“The Catalyst Scholars Fund begins to position Indiana as the go-to location for innovation and technology implementation in Advanced Chemistry manufacturing,” said Central Indiana Corporate Partnership (CICP) CEO Melina Kennedy. “CICP and its initiatives, BioCrossroads and AgriNovus, are pleased to help align these CEOs, university presidents, and ecosystem partners around a single vision: making Indiana the national hub where world-class academic researchers and industry partners come together to strengthen our nation’s most critical supply chains.”

“The Catalyst Scholars Fund builds on IU’s longstanding strengths in the life sciences and accelerates the momentum of IU LAB to rapidly translate research into innovation that fuels Indiana’s competitiveness,” said Indiana University President Pam Whitten. “As Indiana’s largest research institution with a statewide footprint, IU brings unmatched scale, depth, and capability to this effort. By joining forces with the other initiative partners and industry leaders, we are creating research clusters and recruiting talent that will help secure the nation’s medicine and food supply while opening new opportunities for Hoosiers in every corner of the state.” 

“From its two Nobel Prizes in Chemistry to the recently launched One Health strategic priority, Purdue is ready to work with industry partners to develop breakthrough research and excellence at unparalleled scale in talent pipeline through four chemistry-related departments, thus securing critical supply chains onshore and positioning our state as the default destination for advanced chemistry innovation,” said Purdue University President Mung Chiang. “The Catalyst Scholars Fund and the visionary support from Lilly Endowment accelerate our efforts to build the infrastructure and recruit and retain the best faculty in advanced chemistry.” 

“Throughout our history, the University of Notre Dame has been guided by its Catholic mission and our founder’s vision to be a ‘powerful means for doing good in this country,’” said Rev. Robert A. Dowd, C.S.C., University of Notre Dame president. “By supporting advanced chemistry efforts that help to develop our nation’s early career workforce and to reshore manufacturing in critical areas, the Catalyst Scholars Fund reflects our ongoing commitment to harnessing discovery and collaboration, particularly in service of the most vulnerable and underserved in society. These efforts build upon our existing leadership of major initiatives in this space, including the NSF-funded Center for Bioanalytic Metrology and the Center for Computer Aided Synthesis. We look forward to working alongside our industrial and academic partners to realize the vision of Catalyze Indiana and strengthen the health and capacity of our state.” 

Robert A. Coons, President, Rose-Hulman Institute of Technology shared, “I hope every Rose-Hulman graduate leaves with not only knowledge, but a passion for innovation and a drive to keep discovering new ways to solve hard problems. The Catalyst Scholars Fund amplifies those instincts across Indiana’s higher education institutions, empowering faculty and students to take smart risks, push the boundaries of what’s possible in advanced chemistry, and create technologies that will secure critical supply chains and improve lives for years to come.”  

Indiana is uniquely positioned to become the nation’s epicenter for advanced chemistry manufacturing, with global life sciences leaders, top-tier research universities, and a deep manufacturing base that already generates more than $43 billion annually and employs nearly 40,000 Hoosiers in advanced chemistry-related sectors. By prioritizing talent through the Catalyst Scholars Fund, Indiana is building the research depth and technical capacity required to support workforce training and supply chain infrastructure. 

The program also promotes statewide collaboration through coordinated equipment sharing agreements among universities, maximizing the impact of infrastructure investments. Major analytical instruments and specialized facilities enabled through the fund will be available to researchers across institutions. 

Industry partners including Eli Lilly and Company, Elanco Animal Health, and Corteva will help inform annual technology priorities and engage directly with recruited scholars through sponsored research, advisory input, and collaborative programs. This structure ensures that academic research remains aligned with the real manufacturing challenges facing companies operating in food, medicine, and advanced materials. 

“Modern medicines are increasingly complex to manufacture,” said David A. Ricks, Chair and CEO of Eli Lilly and Company. “Advancing the technologies that make production more efficient and reliable is essential to keeping supply secure and ensuring access for patients. This investment deepens Lilly’s collaboration with Indiana’s leading research universities and advanced chemistry experts, and Lilly is excited to work with the researchers recruited through the Catalyst Scholars Fund to help translate innovation into impact.”  

Additional Perspectives from Initiative Partners  

Chuck Magro, CEO, Corteva  
“Innovation in advanced chemistry and manufacturing processes is essential because as the world grows, we will need to grow more food on the same amount of land, manage our environmental footprint, and strengthen the food  supply chain farmers and Hoosiers depend upon. The Catalyst Scholars Fund creates exactly the kind of industry-university partnerships we need, bringing world-class scientists together with global agriculture leaders to turn new ideas into practical tools that help farmers do what they do best – feed the world.”  

Jeff Simmons, President and CEO, Elanco Animal Health 
“When people find their ‘why,’ they go further than they ever imagined, and the same is true for regions and ecosystems. The Catalyst Scholars Fund gives Indiana researchers and innovators a compelling purpose: supporting the health and wellbeing of pets and increasing the availability and affordability of protein that the world is counting on. Further, we’re creating a destination for global talent that wants to make a real difference in animal health and the future of food.” 

### 

About Central Indiana Corporate Partnership (CICP) 
The Central Indiana Corporate Partnership (CICP) was formed in 1999 to bring together the chief executives of the region’s prominent corporations, foundations and universities in a strategic and collaborative effort dedicated to Indiana’s continued prosperity and growth. To advance this mission, CICP sponsors five key talent and industry sector initiatives, AgriNovus Indiana, Ascend Indiana, BioCrossroads, Conexus Indiana,  and TechPoint, each of which addresses challenges and opportunities unique to its respective area: agbiosciences, talent and workforce development, life sciences, advanced manufacturing and logistics, and technology. CICP Foundation, Inc. operates exclusively for the benefit of and carries out the mission of CICP by engaging and supporting its charitable activities. To learn more about the CICP, visit www.cicpindiana.com. 

About BioCrossroads 
BioCrossroads is a catalyst for life sciences innovation and growth in Indiana. As an initiative of the Central Indiana Corporate Partnership, BioCrossroads connects industry leaders, research institutions, investors, and entrepreneurs to advance breakthrough discoveries, accelerate startups, strengthen manufacturing, and develop talent. Through strategic partnerships and targeted investments, BioCrossroads has helped position Indiana as the nation’s leading state for life sciences and pharmaceutical exports. Visit www.biocrossroads.com to learn more about BioCrossroads. 

About AgriNovus Indiana 
AgriNovus Indiana, a branded initiative of the Central Indiana Corporate Partnership (CICP), is a non-profit organization focused on advancing the agbioscience sector by connecting and convening stakeholders to deliver innovative ways to inspire and attract agbiosciences talent, companies and innovation to the state. Learn more at www.AgriNovusIndiana.com. 

About Lilly Endowment Inc. 
Lilly Endowment Inc. is an Indianapolis-based private foundation created in 1937 by J. K. Lilly and his sons, Eli and J.K. Jr., through gifts of stock in their pharmaceutical business, Eli Lilly and Company. While those gifts remain the financial bedrock of the Endowment, the Endowment is a separate entity from the company, with a distinct governing board, staff and location. In keeping with its founders’ wishes, the Endowment supports the causes of community development, education and religion. While the Endowment funds programs throughout the United States on an invitational basis to support these causes, especially in the field of religion, it maintains a special commitment to its founders’ hometown, Indianapolis, and home state, Indiana. 

BioCrossroads Launches BioSignals, a New Podcast Spotlighting Indiana's Life Sciences Momentum 

BioCrossroads is proud to launch BioSignals, a new podcast dedicated to decoding the pulse of Indiana’s rapidly growing life sciences sector. 

Hosted by Vince Wong, President and CEO of BioCrossroads, BioSignals is designed to amplify the compelling stories, breakthrough innovations, and bold leadership shaping Indiana’s position as a global life sciences hub.

“As we’ve watched the Indiana life sciences ecosystem transform into a global powerhouse, the challenge is that not enough people know that about us,” said Wong in the inaugural episode. “So, we created this podcast to transcend borders and share these stories with the world.”

That mission is backed by real momentum. In 2024, Indiana became the nation’s leader in life sciences exports, surpassing California. This is a milestone that reflects the scale and strength of the state’s life sciences industry. 

For the first episode, Wong is joined by a guest whose career reflects the history and trajectory of Indiana’s ecosystem: Dan Peterson, Vice President of Industry and Government Affairs at Cook Group and Chair of the BioCrossroads Board of Directors.  Peterson has been closely connected to BioCrossroads since its earliest days and has spent nearly four decades at Cook, one of the companies that helped shape Indiana’s life sciences foundation. 

“This is one of the benefits of being around a long time,” Peterson joked. “You can provide the historical context.” 

Peterson reflected on the formation of BioCrossroads in 2002, describing a moment when Indiana already had world-class life sciences assets, but lacked a mechanism to connect them. 

At the time, Indiana’s strengths were already clear; the orthopedics sector in Warsaw, major pharmaceutical leadership in Central Indiana, and minimally invasive medical device innovation anchored by Cook in Bloomington. Yet, despite the scale of these players, collaboration across regions and subsectors was limited. 

“We had amazing life sciences assets in this state… and yet none of us really did anything together,” said Peterson. “There was not a mechanism for all of us to come together and look at common, non-competitive issues.” 

BioCrossroads was created to serve as that mechanism by bringing leaders together to align strategy, tell a collective story, and pursue opportunities that would strengthen the ecosystem as a whole. Peterson noted that early BioCrossroads work involved deep research, funded studies, and strategic planning to identify where Indiana could lead. But one milestone stands out as a defining turning point: the creation of the Indiana Bioscience Research Institute (IBRI). 

“It was the first time where we… didn’t just talk about the strategy,” said Peterson. “We brought it to life.” 

Peterson described the IBRI’s formation as a powerful example of what can happen when corporate leaders, state government, local partners, and community stakeholders align behind a shared vision. He credited the initiative’s momentum to collaborative leadership, including then-Eli Lilly CEO John Lechleiter, who helped challenge the ecosystem to think bigger. 

Today, the IBRI continues to grow into its role as a key statewide asset driving research, innovation, and long-term competitiveness. 

Wong and Peterson also discussed Indiana’s unique position in the national life sciences landscape. One of the state’s defining advantages is its ability not only to innovate, but to manufacture. 

“We not only innovate it here and develop it here,” said Peterson. “We make it here.” 

That combination has become a major differentiator as Indiana continues to attract new investments and expand its global reach. It is also a central focus of BioCrossroads’ 10-year life sciences sector strategy, launched in January 2024. 

The strategy is built around four pillars: 

  • Advancing innovation and entrepreneurship 
  • Expanding life sciences manufacturing 
  • Strengthening workforce development 
  • Elevating Indiana’s global life sciences brand 

Peterson emphasized that all four pillars are critical, and that their combined impact will help Indiana grow more aggressively and at greater scale. Every time visitors from outside the state see the ecosystem firsthand, he noted, the reaction is the same: Indiana has far more life sciences capability than most people realize. 

The conversation also offered listeners a deeper look at Cook Group, a privately held global medical device company that has remained deeply rooted in Indiana since its founding. Peterson shared Cook’s entrepreneurial beginnings: Bill and Gayle Cook started the company in a spare bedroom in Bloomington with their one-year-old son. Today, Cook employs 12,000 to 13,000 people worldwide, with operations across Indiana including Bloomington, Indianapolis, and West Lafayette. 

Cook specializes in minimally invasive medical devices, which Peterson described as technologies that allow clinicians to diagnose and treat conditions through small punctures rather than open surgery, all guided by advanced imaging. One example of how far medicine has come, he said, is the disappearance of “exploratory surgery” as a common practice. 

“That phrase is gone,” said Peterson. “That doesn’t happen anymore because of the advancements in imaging paired with the devices that we make.” 

Wong noted that one of the most underappreciated aspects of Cook’s impact is how its innovation culture has generated new companies and new industry branches throughout Indiana. Peterson highlighted examples including Cook-founded ventures that later became major employers and anchors in the region, such as Cook Pharmica (now Novo Nordisk) and Cook Pharmaceutical Solutions (later acquired by Baxter and spun into a new company). 

The result is what Wong described as a “Cook coaching tree,” a growing network of alumni, spinouts, and downstream innovation that continues to strengthen the ecosystem. 

Peterson also discussed how Cook’s culture extends beyond product innovation into community impact. When Cook identifies a challenge that affects workforce stability or quality of life, the company is willing to “lean in” and help build solutions. One major example: workforce housing. In response to housing shortages in Southern Indiana, Cook has taken direct action to help develop affordable housing in communities such as Owen County and Orange County, with plans to expand those efforts further. Cook has also partnered with organizations like Goodwill to create workforce opportunities through an FDA-approved medical device manufacturing facility on Indianapolis’ Near East Side, supporting individuals who historically have had limited access to stable employment. 

One of the most exciting innovations discussed in the episode was Cook’s work in interventional MRI, a next-generation platform that could redefine how minimally invasive procedures are performed. Traditionally, these procedures rely on X-ray guidance, which exposes both patients and clinicians to radiation and often requires contrast dye. Interventional MRI could dramatically reduce those burdens while offering far greater imaging precision. 

Cook has partnered with Siemens to co-develop a platform that enables clinicians to perform minimally invasive procedures using MRI guidance—opening the door to earlier-stage treatments, including potential breakthroughs in cancer care The platform launched in Europe in fall 2025, with a broader U.S. rollout expected this spring. 

“It’s really an early-stage platform that could revolutionize a big part of procedural medicine,” said Peterson. 

BioSignals’ inaugural episode sets the tone for what the podcast aims to deliver: thoughtful conversations with leaders who are shaping the future of health, science, and innovation, right here in Indiana. 

With guests like Dan Peterson, the series begins with a strong reminder that Indiana’s life sciences success is not accidental. It is the result of decades of collaboration, long-term strategy, and an ecosystem willing to invest in bold ideas. 

And now, BioSignals will help ensure those stories are heard well beyond Indiana’s borders. 

Listen to the first episode of BioSignals now and subscribe for upcoming conversations featuring innovators, executives, and change-makers from across Indiana’s life sciences community. 

BioCrossroads Launches Startup Hub, a New Centralized Platform for Indiana’s Life Sciences Startup Ecosystem 

INDIANAPOLIS [January 22, 2025] – BioCrossroads today officially launched the BioCrossroads Startup Hub, a new, comprehensive ecosystem platform designed to serve as a centralized front door for Indiana’s life sciences startup community. Built as a continually evolving resource, this online hub brings together funding pathways, mentorship, regulatory and clinical resources, startup visibility, and ecosystem connections in one place. 

The platform targets a longstanding challenge within Indiana’s innovation economy: while the state is home to one of the strongest life sciences ecosystems in the country, the resources that support startups have historically been fragmented across many organizations and websites. That fragmentation can slow momentum for founders, limit visibility for investors, and create unnecessary barriers to growth. 

The BioCrossroads Startup Hub is designed for the multiple stakeholders critical to a thriving startup ecosystem— researchers and innovators exploring commercialization; investors seeking Indiana-based life sciences opportunities; and ecosystem organizations supporting startup growth. The site will equip founders and investors with the full set of tools needed to access and navigate Indiana’s life sciences ecosystem.  

“Indiana is number one in the nation for life sciences and pharmaceutical exports, and we have world-class research, talent, and industry leadership,” said Vince Wong, President and CEO of BioCrossroads. “The BioCrossroads Startup Hub helps translate these strengths into a thriving startup ecosystem.  By curating and aggregating critical resources in one place, this platform gives founders clarity, connects investors to promising startups, and reinforces Indiana’s advantage as a connected, high-performing life sciences ecosystem.” 

The platform includes: 

  • An interactive startup journey map with stage-specific guidance
  • Indiana-specific funding pathways, including grants, angel networks, and venture capital
  • A searchable directory of life sciences startups
  • Mentorship and peer support programs
  • Clinical data assets and regulatory resources
  • University innovation and commercialization programs 

The resource hub launch comes on the heels of last week’s announcement of the launch of BioCrossroads’ new early-stage venture fund, Crossroads Health Ventures (CHV). The fund has secured more than $21 million in commitments and will begin deploying capital in early 2026. CHV is another example of BioCrossroads’ focus on providing critical support for promising innovations.  

The BioCrossroads Resource Hub also advances BioCrossroads’ broader mission by expanding engagement with founders, increasing ecosystem visibility, and strengthening Indiana’s innovation pipeline. As a dynamic platform, it will be regularly updated with new startups, funding sources, events, and resources, with built-in submission tools to encourage ongoing community participation. 

Learn more at: BioCrossroads.com/Startup. 

About BioCrossroads 

Established as a catalyst to advance, grow, and invest in Indiana’s life sciences sector, BioCrossroads is an initiative of the Central Indiana Corporate Partnership (CICP). It supports the region’s existing enterprises and encourages new business development. The initiative fosters public-private collaboration by uniting a diverse range of academic, industry, and philanthropic stakeholders, all collectively focused on advancing Indiana’s life sciences sector. Committed to supporting the growth of capital investments and talent development, BioCrossroads provides support to both existing and new life sciences enterprises, including the Indiana Health Information Exchange, OrthoWorx, and the Indiana Biosciences Research Institute. BioCrossroads champions the advancement of cutting-edge research and development, plays a crucial role in building and nurturing a robust talent pipeline, and is dedicated to establishing Indiana as a thriving hub for life sciences manufacturing. To learn more about BioCrossroads, visit biocrossroads.com.  

Crossroads Health Ventures Announces First Fund with More Than $21 Million Committed to Strengthen Indiana’s Life Sciences Innovation Pipeline

INDIANAPOLIS (Jan. 21, 2026) – Crossroads Health Ventures (CHV) announced its launch of a new early-stage venture fund created to accelerate the growth of Indiana’s life sciences startups and reinforce the state’s global leadership across human, animal, and plant health innovation.

The fund has secured more than $21 million in commitments from strategic and institutional partners such as Eli Lilly and Company, Corteva, Elanco Animal Health, Indiana University, Parkview Health, and the State of Indiana through the Economic Development Corporation (IEDC). CHV will begin deploying capital in early 2026.

“Indiana is one of the nation’s strongest and most vibrant life sciences hubs, and Crossroads Health Ventures is an important next step in fueling our state’s innovation economy,” said Vince Wong, President and CEO of BioCrossroads and Crossroads Health Ventures. “With the State of Indiana’s transformational commitment and the leadership of our industry, academic, and investment partners, Crossroads Health Ventures fills a critical early-stage funding gap to help translate breakthrough ideas into high-growth Indiana companies that ultimately make a global impact.” 

“This collaborative initiative is a transformative opportunity to propel Indiana’s already strong One Health economy,” said Secretary of Commerce David J. Adams. “Through Crossroads Health Ventures, the state–in partnership with industry and regional leadership–is lifting up entrepreneurs and startups to drive innovation across human, animal and plant health, creating next-generation solutions and solidifying Indiana’s global leadership.”

Indiana’s life sciences sector is already experiencing historic momentum. The state now ranks #1 in the U.S. for life sciences exports driven by global industry leaders, world-class research universities, and a highly skilled workforce. Access to early-stage capital is important to startups, and CHV is designed to address this need. With coordinated statewide leadership, a strong pipeline of promising innovations, and a dynamic entrepreneurial ecosystem, the fund will help ensure that more of Indiana’s life science discoveries grow into Indiana-based companies, creating jobs, attracting investment, and advancing solutions that improve health around the world.

“Indiana University is proud to join this collaborative effort to advance life-changing innovation across our state,” said Pamela Whitten, President, Indiana University. “Crossroads Health Ventures will help ensure that breakthrough discoveries—from IU researchers and entrepreneurs throughout Indiana—have the support they need to reach patients, clinicians, and communities. This initiative reflects the strength of Indiana’s research ecosystem and our shared commitment to fueling economic growth through scientific discovery.”

CHV will invest in 15–20 early-stage U.S.-based companies with assets that align with the strategic priorities of its partners, with the flexibility to concentrate investments in Indiana-based startups where there is strong alignment, differentiated opportunity, and potential for outsized return. The fund will support companies through key development and commercialization milestones and will provide follow-on capital to help founders reach critical inflection points.

“At Elanco, we know that innovation flourishes in strong, connected ecosystems that serve as pipelines for the next generation of technologies. Leveraging the strong support from Indiana’s unique One Health ecosystem with global leaders in human, animal, and plant health sectors, Crossroads Health Ventures provides the early-stage capital and strategic partnerships necessary for emerging life sciences companies to thrive,” said Jeff Simmons, President and CEO of Elanco Animal Health. “We believe Indiana is the most ideal location to accelerate life sciences innovations given the collaboration of leading global companies, top-tier research universities, and a strong public partnership that creates access to capital, expertise and manufacturing and pilot capabilities.”

A cross-initiative collaboration among BioCrossroads, TechPoint, and AgriNovus Indiana, CHV leverages more than 60 years of combined investment, startup, and corporate operating experience. Through deep networks, proprietary deal flow, and an integrated platform of entrepreneurial support, CHV is designed to accelerate startups’ growth, attract outside capital, and expand Indiana’s life sciences economy.

About Crossroads Health Ventures
As part of BC Initiative, Inc., a for-profit entity, Crossroads Health Ventures is an early-stage venture fund investing in human, animal, and plant health assets and enabling technologies. Powered by BioCrossroads, TechPoint, and AgriNovus Indiana, the fund sources high-quality deals, supports founders, and advances Indiana’s leadership in life sciences innovation.

BioCrossroads’ AXIS Mentoring Program: Meet the First Two Cohorts

A core tenet of BioCrossroads’ mission is bringing people from Indiana’s life science sector together to increase our collective impact. We convene to collaborate. And no program better exemplifies these efforts than our AXIS mentoring program, which is designed to provide structured, team-based mentorship to early-stage life sciences entrepreneurs.  

What sets AXIS apart from other mentoring efforts is its focus on connection without institutional boundaries. AXIS is supported by powerful partners like IU, Purdue, Notre Dame, 16 Tech, Heartland BioWorks, and is operated through BioCrossroads. Entrepreneurs from anywhere in Indiana and at any stage can participate. BioCrossroads has recruited mentors from across the life sciences, bringing a wide range of professional and personal experience. Our mentor pool includes some of Indiana’s leading life sciences professionals, motivated to help advance and scale the next generation of innovation. 

The vision for AXIS is clear: cultivate a vibrant, inclusive, and interconnected life sciences ecosystem, with mentorship as the foundation for translating ideas into impact and retaining our top talent in the state. AXIS will play a critical role in helping early career scientists and emerging companies avoid common pitfalls, accelerate their growth, expand career pathways, and navigate the complex regulatory, funding, and commercialization environments unique to the life sciences sector. Drawing from the proven model of MIT’s Venture Mentoring Service (VMS), the program builds a strong support system for individuals navigating the challenges of scientific innovation, commercialization, and founder growth. 

Launched by BioCrossroads in 2025, AXIS has already supported two cohorts that have pitched their ideas and begun advancing their work.  

How You Can Get Involved 

  • Apply as a mentee: Early-career scientists, researchers, and life sciences founders are encouraged to join the next cohort. 
  • Become a mentor: Seasoned professionals can share expertise and make tangible impact. 
  • Partner and support: Regional stakeholders can bolster AXIS’s reach and deepen its ecosystem influence. 

The success of AXIS hinges on its collaborative spirit—mentors, mentees, partners, and supporters working together to nurture vibrant, sustainable growth in Indiana’s life sciences sector. 

Cohort 1 

Qwyn AI
AXIS Mentee: Adam Martin 
Developer of an artificial intelligence-powered quality management platform designed to help life sciences organizations accelerate investigations, automate root cause analysis and prevent recurrence of quality issues. The company offers guided investigation workflows, automated documentation, regulatory intelligence, and trend detection, enabling pharmaceutical and biotechnology manufacturers to maintain compliance, reduce cycle times, and improve product quality. 

IndiAide Inc.
AXIS Mentee: Alyssa Antcliff 
Developer of a daily task management platform designed to centralize the management of important health and personal information. The company’s platform improves functional independence and continuity of care for people with medical complexities, cognitive impairments, those who are aging in place, and their families, enabling clients to manage daily tasks and wellbeing for individuals with cognitive impairment. 

Quornix 
AXIS Mentee: Dr. Julia van Kessel and Dr. Laura Brown 
Developer of small-molecule therapeutics that target bacterial quorum sensing to disrupt pathogenic behavior without directly killing bacteria. The company’s approach aims to reduce antimicrobial resistance while addressing infectious disease challenges in human health and aquaculture. Quornix is based in Bloomington, Indiana, and was formed around Indiana University–derived research. 

Delta Ops AI 
AXIS Mentee: Dr. Pengyi Shi 
Operator of workforce management intended to optimize staff allocation in healthcare settings. The company’s platform uses advanced optimization algorithms to assign nurses effectively across daily shifts and long-term schedules, considering factors such as unit needs and medical campus requirements, enabling healthcare organizations to maximize operational efficiency, reduce labor costs, and improve care delivery by ensuring the right staff are in the right place at the right time.  

GoldiloxBio 
AXIS Mentee: Dr. Milos Marinkovic 
Developer of physiologically relevant preclinical testing platforms that replicate tissue-specific extracellular matrix environments to improve cardiomyocyte function and cardiac toxicity assessment. The company’s technology is designed to generate more predictive safety and efficacy data earlier in the drug development process. Its platform serves biopharmaceutical companies seeking to reduce late-stage clinical failures.
 

Peak Mind
AXIS Mentee: Alicia Mckoy 
Operator of an employee well-being application designed to help businesses build connections and a culture of care for their employees. The company’s application measures stress levels and offers coping mechanisms through a library of tools, enabling organizations in education and public safety to improve employee well-being and reduce stress-related expenses. 

Amplicore, Inc.
AXIS Mentee: Dr. Stacey Gruber 
Developer of injectable therapeutic drugs designed to treat degenerative musculoskeletal disorders to serve unmet medical needs. The company’s drugs promote cartilage regeneration and suppress enzymatic activities to treat degenerative musculoskeletal disorders, enabling healthcare organizations to seamlessly provide relief to patients from joint pain.  

Cohort 2 
 

ReactRX
AXIS Mentee: Dr. Emma Tillman 
Developer of an AI-enabled pharmacovigilance platform designed to transform passive adverse drug reaction reporting into a real-time, interactive safety monitoring system. The company’s platform engages patients beyond pharmacy pickup to collect denominator-aware safety data, enable early signal detection, and deliver actionable insights to pharmaceutical companies, CROs, and regulators.  

Vasculonics
AXIS Mentee: Brad Lawson 
Developer of a disease-modifying therapeutic platform designed to reduce progression and mortality in pulmonary arterial hypertension. The company offers a novel selective aryl hydrocarbon receptor modulator that targets inflammation, oxidative stress, fibrosis, and vascular toxicity, enabling treatment of individuals with pulmonary arterial hypertension, improved quality of life, and survival.  

Narrow-Spectrum Antibiotics Targeting Bacterial Carbonic Anhydrase 
Faculty-Led Research | Company Formation Opportunity
AXIS Mentee: Dr. Daniel Flaherty 
 
Developer of a novel narrow-spectrum antibiotic platform targeting bacterial carbonic anhydrase enzymes to selectively treat drug-resistant pathogens while preserving the gut microbiome. The underlying faculty-led research demonstrates potency against high-priority indications including vancomycin-resistant Enterococcus and drug-resistant Neisseria gonorrhoeae, with applications in both treatment and pre-exposure decolonization. The technology represents a differentiated antimicrobial mechanism with no known competitors in this enzyme class and is currently positioned for startup formation and translational development.  

echoSURE
AXIS Mentee: Raishma Anwar 
Developer of a bedside medical device that verifies nasogastric feeding tube placement using proprietary acoustic sensing and signal-processing technology. The solution enables rapid, point-of-care confirmation without reliance on radiographic imaging. The technology is intended to improve patient safety while reducing delays and costs associated with X-ray confirmation.  

TruePulse Health
AXIS Mentee: Dr. Sujata Punait 
Developer of a software platform that provides continuous, real-time monitoring of autonomic nervous system activity to deliver personalized stress and recovery insights to clinicians. The company’s ANSense platform integrates multi-signal physiological data with advanced analytics to enable earlier detection of autonomic dysfunction and proactive intervention, particularly in maternal care settings. TruePulse Health monetizes its platform through a B2B subscription and setup fee model, with plans to expand into value-based care and broader high-acuity clinical markets. 

The BioCrossroads Startup Hub: Indiana's Central Platform for Life Sciences Innovation

Building a life sciences company in Indiana means tapping into one of the strongest ecosystems in the country. The resources, expertise, and support are here, and we’re making them easier than ever to access.

On January 20, BioCrossroads will launch the BioCrossroads Startup Hub, Indiana’s first centralized platform for life sciences founders, investors, and ecosystem partners. This new hub brings together funding pathways, startup directories, commercialization resources, mentorship programs, and regulatory guidance—everything early-stage companies need to grow in Indiana.

Why This Matters

Indiana leads the nation in life sciences and pharmaceutical exports. We’re home to global industry leaders, world-class research universities, and a thriving community of entrepreneurs building the next generation of healthcare solutions. But historically, the resources supporting these startups, like funding opportunities, mentorship programs, regulatory guidance, clinical assets, have been spread across dozens of organizations and websites.

That fragmentation slows momentum for founders who need clarity, limits visibility for investors seeking opportunities, and makes it challenging for our ecosystem to move at the speed innovation demands. The BioCrossroads Startup Hub solves that problem by bringing everything together in one place. The platform is built for founders at any stage, whether you’re a researcher exploring commercialization for the first time, a startup scaling toward Series A, or an investor looking for Indiana-based opportunities.

What You’ll Find
  • An interactive startup journey map with stage-specific guidance tailored to where you are today
  • Indiana-specific funding pathways, including grants, angel networks, and venture capital sources
  • A searchable directory of life sciences startups across the state
  • Mentorship and peer support programs to help navigate the unique challenges of building in life sciences
  • Clinical data assets and regulatory resources critical for product development and commercialization
  • University innovation and commercialization programs connecting academic research to market applications
Built to Evolve

The Hub is designed as a living platform that will grow alongside Indiana’s ecosystem, and will continue to be updated with new startups, funding sources, events, and resources.

Indiana’s strength in life sciences manufacturing, talent development, and research excellence creates a foundation that few states can match. The BioCrossroads Startup Hub helps ensure our startup ecosystem leverages that foundation to its fullest potential.

The platform launches January 20 at BioCrossroads.com/Startup.

We’re excited to see what you build.

Meeting the Moment: Elevating Indiana’s Life Sciences Leadership

 

Workforce development has paid dividends for Indiana’s life sciences sector. The Hoosier State leads the nation in both pharmaceutical and life sciences exports. The sector employs 70,000 Hoosiers across 3,200 establishments and contributes $99 billion to Indiana’s economy. And the average wage among life sciences professionals – $148,000 – is well ahead of the state’s average.

But when it comes to leadership, there’s no such thing as a finish line. To stay competitive with the likes of Boston and San Diego, workforce development remains a top priority for Indiana’s life sciences ecosystem.

And on June 12, leading professionals and recruiters met to exchange perspectives at the quarterly FrameWORX hosted by BioCrossroads.

Gone are the days when recruiting started in college and job training moved along slowly. Today, employers and employees alike are looking for dynamic, life-changing opportunities right out of the gate. In Indiana, industry visibility starts as early as middle school. Internships with substance and ongoing training and development for professionals are critical parts of the mix.

Zachary Haller, the practice lead who supports lab services and scientific solutions at Actalent, said drivers for people seeking new opportunities are clear.

“Not only is the labor market changing but so are the desires of candidates,” Haller told a capacity crowd at the Indiana Biosciences Research Institute at 16 Tech. “People want to work in meaningful jobs. They don’t want to just work or just get a paycheck. And people want a personalized plan. Not a lot of people are getting those experiences.”

To keep pace, Indiana is looking at next-level platforms. Indiana’s designation as a tech hub means BioTrain will produce job-ready professionals who want careers in biomanufacturing. BioTrain is part of the Heartland BioWorks Tech Hub, a $51 million initiative supported by the U.S. Economic Development Administration and spearheaded by the Applied Research Institute (ARI) in collaboration with Purdue University, Ivy Tech Community College, and BioCrossroads. BioTrain will address the projected labor shortage in Indiana’s biotech industry.

Indiana also is adopting the Swiss apprenticeship model to enhance career readiness among high school students, particularly in the life sciences sector – part of a broader effort to provide students with practical, paid work experiences alongside their education.

“Life sciences and health care often have synergies with people moving back and forth between the sectors,” said Vince Wong, president and CEO of BioCrossroads. “We have strategies at different levels: for K-12, for college, and for those already working in the industry. We are developing strategies for all groups to meet people where they are.”

workforce resources

Meet the partners powering Indiana’s life sciences and healthcare workforce

The employers, educators, and organizations featured here are building real pipelines, aligning training with industry demand, creating new pathways into scientific and clinical roles, and helping employers attract and grow the teams they need to compete. Each one offers practical tools, proven approaches, and direct ways to support your talent strategy.

Actalent

Data-driven talent solutions across scientific and clinical roles

Actalent partners with companies to deliver customized workforce solutions, with deep expertise in clinical, scientific, and engineering roles. Their data-informed approach helps employers stay agile in a competitive talent market.
www.actalentservices.com


Ascend Indiana

Matching talent to high-demand roles with personalized career navigation

Ascend Indiana connects employers with qualified talent through a unique blend of one-on-one career guidance and tech-enabled matching tools. Their employer partnerships help streamline hiring pipelines while opening doors to high-demand jobs for Indiana residents.
www.ascendindiana.com


IBRI Internship Program

Hands-on experience in translational research

The Indiana Biosciences Research Institute (IBRI) offers a competitive internship program that provides early-career scientists with exposure to applied, translational research in a collaborative environment. The program supports both student development and employer workforce needs through mentorship and meaningful lab experiences.
www.indianabiosciences.org 


IU Health

Creating upward mobility through continuous education
As one of the state’s largest healthcare employers, IU Health invests in its people. Their career development initiatives—from tuition support to pathway programs—help employees build long-term careers while staying responsive to workforce needs across the system.
www.iuhealth.org


Ivy Tech Community College

Industry-aligned training and credentialing programs
With campuses across Indiana, Ivy Tech offers accessible, flexible training that is closely aligned with employer needs—whether it’s credentials in biotech manufacturing, clinical support, or quality systems. Their programs help both new entrants and current employees build in-demand skills.
www.ivytech.edu

Discover more career-focused resources in the BioCrossroads Career Hub

INDIANAPOLIS (May 8, 2025) – BioCrossroads, the Central Indiana Corporate Partnership initiative established as a catalyst to advance, grow, and invest in Indiana’s life sciences sector, today announced two new appointments to its Board of Directors and recognized the contributions of three long-serving members whose leadership has helped shape the state’s life sciences ecosystem.

Richard Church, Chief Growth & Strategy Officer at Parkview Health, has joined the BioCrossroads Board of Directors. Since arriving at Parkview in 2022, Church has led the organization’s strategic growth initiatives, focusing on long-term innovation and access to care across the region. Prior to his current role, Church served as co-leader of the national healthcare practice group at K&L Gates, where he advised health systems on joint ventures, regulatory compliance, clinical integration, and mergers and acquisitions. His legal and regulatory expertise, paired with  his leadership of Parkview Health’s innovation initiatives , will be instrumental as BioCrossroads continues its mission to advance Indiana’s leadership in life sciences.

Also joining the Board is Dr. David Umulis, Senior Vice Provost at Purdue University in Indianapolis. A nationally recognized leader in systems biology and biomedical engineering, Dr. Umulis has led major initiatives in computational modeling, tissue development, and data science. He previously served as head of Purdue’s Weldon School of Biomedical Engineering and helped establish the university’s Integrative Data Science Initiative. His deep scientific expertise and commitment to interdisciplinary collaboration align with BioCrossroads’ focus on translational research and workforce development.

Church succeeds Dr. Michael J. Mirro, who concludes over a decade of service on the Board. A distinguished physician and researcher, Dr. Mirro has served as Chief Academic Research Officer at Parkview Health since 2014 and holds faculty appointments at the Indiana University School of Medicine and IU’s bioinformatics program. He has authored more than 50 peer-reviewed publications and serves on the editorial board of the Cardiovascular Digital Health Journal. The Parkview Mirro Center for Research and Innovation—named in his honor—stands as a testament to his impact on medical research and innovation. Most recently, he helped launch the MedTech Global Gateway, connecting international med-tech companies with Indiana’s clinical and economic development resources. BioCrossroads extends its sincere gratitude for Dr. Mirro’s lasting contributions to the state’s innovation infrastructure.

Dr. Umulis succeeds Dan Hasler, Chief Operating Officer of Purdue University in Indianapolis, who has brought invaluable cross-sector insight to the Board. Hasler previously served as President of the Purdue Research Foundation, guiding commercialization and entrepreneurial strategy for Purdue’s intellectual property portfolio. He also held the role of Indiana’s Secretary of Commerce, where he helped attract a record number of companies to the state, and spent more than 30 years at Eli Lilly and Company. Hasler’s career has spanned business, government, and higher education, making him a key voice in shaping BioCrossroads’ vision for growth. The organization is deeply appreciative of his contributions.

In addition to these changes, BioCrossroads also recognizes the extraordinary service of Dr. Craig Brater, who concludes his tenure on the Board of Directors after two decades of service. As a founding Board member since 2004, Dr. Brater brought a visionary perspective to BioCrossroads’ mission to grow and strengthen Indiana’s life sciences sector. His distinguished career as Dean of the Indiana University School of Medicine and Vice President for Life Sciences at Indiana University positioned him as a driving force behind initiatives that fostered research, collaboration, and innovation across the state. Dr. Brater’s contributions have had a profound and lasting impact on BioCrossroads and the broader life sciences ecosystem, and we are deeply grateful for his steadfast leadership, partnership, and commitment over the years.

“These Board transitions reflect the strength and depth of Indiana’s life sciences leadership,” said Vince Wong, President and CEO of BioCrossroads. “We are proud to welcome Richard and David, whose expertise and perspectives will help guide our strategic direction. At the same time, we are deeply grateful to Michael,  Dan, and Craig for their years of service and for the impact they’ve made not only on BioCrossroads, but on the broader innovation ecosystem we all work to grow.”

###

About BioCrossroads

Established as a catalyst to advance, grow, and invest in Indiana’s life sciences sector, BioCrossroads is an initiative of the Central Indiana Corporate Partnership (CICP). It supports the region’s existing enterprises and encourages new business development. The initiative fosters public-private collaboration by uniting a diverse range of academic, industry, and philanthropic stakeholders, all collectively focused on advancing Indiana’s life sciences sector. Committed to supporting the growth of capital investments and talent development, BioCrossroads provides support to both existing and new life sciences enterprises, including the Indiana Health Information Exchange, OrthoWorx, and the Indiana Biosciences Research Institute. BioCrossroads champions the advancement of cutting-edge research and development, plays a crucial role in building and nurturing a robust talent pipeline, and is dedicated to establishing Indiana as a thriving hub for life sciences manufacturing. To learn more about BioCrossroads, visit biocrossroads.com.

News from BioCrossroads

BioCrossroads Blog
Dr. Wade Clapp Named 2026 Watanabe Life Sciences Champion of the Year

October 29, 2026

BioCrossroads Blog
BioCrossroads 2026 Life Sciences Summit Explores AI’s Role in Shaping the Future of the BioHeartland

October 29, 2026

BioCrossroads Blog
FrameWORX Recap: Indiana's Medical Device Ecosystem

September 9, 2026

BioCrossroads Blog
AXIS: Mentor and Mentee Q&A

August 31, 2026

Press Releases
Gov. Braun Announces $173 Million RayzeBio Investment, 100 New Jobs as Indiana's Life Sciences Sector Grows

August 28, 2026

BioCrossroads Blog
INCAP Apprenticeship Showcase Event to Bring Careers Opportunities to Life for Students

August 26, 2026

Introducing Provena Consortium: A New Name for an Established Clinical–Genomic Data Asset Read the Press Release →
+